Zenas Q3 2024: Net loss $38.6M; raised $258.7M IPO; obexelimab INDIGO topline by end 2025

Zenas BioPharma, Inc.

2024-Q3 EPS reported -$28.83

Completed IPO raising $258.7M gross proceeds; cash $386.8M to fund into Q4 2026.
Phase 3 INDIGO (IgG4-RD) completed enrollment; topline results expected by end 2025.
Initiated Phase 2 MoonStone (RMS) and SunStone (SLE); MoonStone results Q3 2025, SunStone topline H1 2026.
Net loss $38.6M vs net income $35.6M (prior year had BMS collaboration); R&D $33.5M vs $9.4M.
Appointed CCO Orlando Oliveira and CLO Jeff Held; out-licensed ZB005 for upfront and milestones.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.